ABUS

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing treatments for chronic hepatitis B virus (HBV) infection. Headquartered in Warminster, Pennsylvania, with research facilities in British Columbia, Canada, the company employs approximately 100 people. Arbutus advances a pipeline of product candidates targeting different stages of the HBV lifecycle, including imdusiran, an RNA interference therapeutic designed to reduce viral antigens, and AB-729, a subcutaneously delivered GalNAc-siRNA therapeutic. The company's proprietary lipid nanoparticle (LNP) technology platform, which enables delivery of nucleic acid-based therapeutics, has been licensed to other pharmaceutical companies and generates royalty revenue. In recent years, Arbutus has focused on advancing its lead HBV programs through clinical trials while defending and monetizing its intellectual property portfolio. The company entered into a notable settlement with Moderna in 2022 regarding LNP patent disputes, securing milestone payments and royalties. Arbutus operates through collaborations with academic institutions and maintains partnerships to advance its research objectives. As a development-stage company, Arbutus does not yet generate product revenue and funds operations through a combination of cash reserves, royalty payments, and strategic licensing agreements. The company focuses exclusively on addressing the significant unmet medical need in chronic HBV treatment, which affects an estimated 300 million people worldwide.